Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Fiona Errington"'
Autor:
Marlous Hall, Jennifer Williams, Fiona Errington-Mais, Tereza Andreou, Rebecca J Brownlie, Robert J Salmond, Mihaela Lorger, Scott Gregory, Fiona James, Christopher Fife, Ashley Sunderland, Clive McKimmie, Samuel Heaton, Zarnaz Hadi, David R Westhead, Alexander Davie, Amber Emmett
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 11 (2024)
Background Brain metastases (BrM) affect up to 60% of patients with metastatic melanoma and are associated with poor prognosis. While combined immune checkpoint blockade of programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CT
Externí odkaz:
https://doaj.org/article/3bcea94ec8a94258978f49f726d9e04e
Autor:
Victoria Jennings, Alan Melcher, Fiona Errington-Mais, Victoria Roulstone, Kevin J Harrington, Galabina Bozhanova, Shane Foo, Martin McLaughlin, Malin Pedersen, John Bell, Pablo Nenclares, Joan Kyula, Lizzie Appleton, Edward Armstrong, Masahiro Ono, Matthew K L Chiu, Anton Patrikeev, Nitya Mohan, Julia Hoebart, Emmanuel Patin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Over the past decade, cancer immunotherapies have revolutionized the treatment of melanoma; however, responses vary across patient populations. Recently, baseline tumor size has been identified as an independent prognostic factor for overa
Externí odkaz:
https://doaj.org/article/2760efb5528c442eb6992610bc801ce3
Autor:
Matthew Holmes, Gina B. Scott, Samuel Heaton, Tyler Barr, Basem Askar, Louise M.E. Müller, Victoria A. Jennings, Christy Ralph, Cathy Burton, Alan Melcher, Peter Hillmen, Christopher Parrish, Fiona Errington-Mais
Publikováno v:
Molecular Therapy: Oncolytics, Vol 29, Iss , Pp 17-29 (2023)
Primary drug resistance and minimal residual disease are major challenges in the treatment of B cell neoplasms. Therefore, this study aimed to identify a novel treatment capable of eradicating malignant B cells and drug-resistant disease. Oncolytic v
Externí odkaz:
https://doaj.org/article/5203c050e9894f55a9405ad6fce9ab42
Autor:
Victoria Jennings, Kevin Harrington, Hardev Pandha, Alan Melcher, Adel Samson, Fiona Errington-Mais, Victoria Roulstone, Eva Crespo-Rodriguez, Galabina Bozhanova, Shane Foo, Emmanuel C Patin, Martin McLaughlin, Malin Pedersen, Richard Vile, Joan Kyula, Jehanne Hassan, Lizzie Appleton, Charleen ML Chan Wah Hak, Gabby Baker, Edward Armstrong, Matthew Chiu, Masahiro Ono
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology of combinations is needed to i
Externí odkaz:
https://doaj.org/article/316204113b0e4019ac28423a26ae7cf2
Autor:
Louise M. E. Müller, Matthew Holmes, Joanne L. Michael, Gina B. Scott, Emma J. West, Karen J. Scott, Christopher Parrish, Kathryn Hall, Sina Stäble, Victoria A. Jennings, Matthew Cullen, Stewart McConnell, Catherine Langton, Emma L. Tidswell, Darren Shafren, Adel Samson, Kevin J. Harrington, Hardev Pandha, Christy Ralph, Richard J. Kelly, Gordon Cook, Alan A. Melcher, Fiona Errington-Mais
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Abstract Background The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies offer the best chance of
Externí odkaz:
https://doaj.org/article/45333d28906e4c79a697ecb02c401857
Autor:
Elisa Fontana, Anguraj Sadanandam, Paul Carter, Nick West, Sandra Demaria, Kevin Harrington, Alan Melcher, David Mansfield, Katharina von Loga, Fiona Errington-Mais, Anna Wilkins, Gift Nyamundanda, Hannah Bye, Chanthirika Ragulan, Yatish Patil, Jennifer Kingston, Daniel Bottomley, Emma Tinkler-Hundal, Jessica Downs, Magnus Dillon, David Sebag-Montefiore, Arish Noshirwani
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Rectal cancers show a highly varied response to neoadjuvant radiotherapy/chemoradiation (RT/CRT) and the impact of the tumor immune microenvironment on this response is poorly understood. Current clinical tumor regression grading systems a
Externí odkaz:
https://doaj.org/article/48882b43944f4a79aa411b08dcce06cb
Autor:
Victoria Jennings, Christopher Parrish, Christy Ralph, Alan Melcher, Adel Samson, Gordon Cook, Fiona Errington-Mais, Matt Coffey, Munitta Muthana, Gemma Migneco, Louise M E Müller, Gina B Scott, Jenny Down, Sancha King, Basem Askar, Babatunde Oyajobi, Karen Scott, Emma West, Elizabeth J Ilett, Michelle Lawson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Multiple myeloma (MM) remains an incurable disease and oncolytic viruses offer a well-tolerated addition to the therapeutic arsenal. Oncolytic reovirus has progressed to phase I clinical trials and its direct lytic potential has been exten
Externí odkaz:
https://doaj.org/article/db50054d7a414d2980de99757b9e839e
Autor:
Fiona Collinson, Alan A. Melcher, Alan Anthoney, Darren J. Newton, Christy Ralph, Fiona Errington-Mais, Hardev Pandha, Richard G. Vile, Kevin J. Harrington, Chris J. Twelves, John Bell, Rebecca Auer, Giles J. Toogood, K.R. Prasad, Monika Lusky, Nicolas Stojkowitz, Kaidre Bendjama, Victoria A. Jennings, Barbara da Silva, Michelle Johnpulle, Jennifer Kingston, Emma Tidswell, Adam Peckham-Cooper, Rajiv V. Dave, Bethany Kuszlewicz, Samantha Turnbull, Karen J. Scott, Jonathan Carmichael, Emma J. West, Adel Samson
Supplementary Figure from Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31a91d9095b10d23365f7a59df1819f1
https://doi.org/10.1158/2326-6066.22544210.v1
https://doi.org/10.1158/2326-6066.22544210.v1
Autor:
Fiona Collinson, Alan A. Melcher, Alan Anthoney, Darren J. Newton, Christy Ralph, Fiona Errington-Mais, Hardev Pandha, Richard G. Vile, Kevin J. Harrington, Chris J. Twelves, John Bell, Rebecca Auer, Giles J. Toogood, K.R. Prasad, Monika Lusky, Nicolas Stojkowitz, Kaidre Bendjama, Victoria A. Jennings, Barbara da Silva, Michelle Johnpulle, Jennifer Kingston, Emma Tidswell, Adam Peckham-Cooper, Rajiv V. Dave, Bethany Kuszlewicz, Samantha Turnbull, Karen J. Scott, Jonathan Carmichael, Emma J. West, Adel Samson
Supplementary Data from Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e7c77efbfb3b8e77a0ae08974c11a08
https://doi.org/10.1158/2326-6066.22544216.v1
https://doi.org/10.1158/2326-6066.22544216.v1
Autor:
Fiona Collinson, Alan A. Melcher, Alan Anthoney, Darren J. Newton, Christy Ralph, Fiona Errington-Mais, Hardev Pandha, Richard G. Vile, Kevin J. Harrington, Chris J. Twelves, John Bell, Rebecca Auer, Giles J. Toogood, K.R. Prasad, Monika Lusky, Nicolas Stojkowitz, Kaidre Bendjama, Victoria A. Jennings, Barbara da Silva, Michelle Johnpulle, Jennifer Kingston, Emma Tidswell, Adam Peckham-Cooper, Rajiv V. Dave, Bethany Kuszlewicz, Samantha Turnbull, Karen J. Scott, Jonathan Carmichael, Emma J. West, Adel Samson
Improving the chances of curing patients with cancer who have had surgery to remove metastatic sites of disease is a priority area for cancer research. Pexa-Vec (Pexastimogene Devacirepvec; JX-594, TG6006) is a principally immunotherapeutic oncolytic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfd6fa47fd5f357dfeeffbe9b9017d6b
https://doi.org/10.1158/2326-6066.c.6550577
https://doi.org/10.1158/2326-6066.c.6550577